CorMedix (CRMD) Tops Q4 EPS by 5c

CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.22, $0.05 better than the analyst estimate of $0.17. Revenue for the quarter came in at $31.2 million versus the consensus estimate of $31 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Hims & Hers chief accounting officer to resign in October
• Q32 Bio (QTTB) files for 6.875M share offering by selling stockholders